Matthew Gall I Teos Therapeutics, Inc. (ITOS) insider trading activity

Matthew Gall is Chief Financial Officer of iTeos Therapeutics, Inc.. Currently has a direct ownership of 89,429 shares of ITOS, which is worth approximately $600,068. The most recent transaction as insider was on Mar 07, 2025, when has been sold 24,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 89.4K

36.68% 3M change

47.99% 12M change

Total Value Held $600,068

Matthew Gall Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 07 2025	BUY Grant, award, or other acquisition	-	24,000 Added 21.16%	89,429 Common Stock
Nov 19 2024	BUY Open market or private purchase	$38,650 $7.73 p/Share	5,000 Added 7.1%	65,429 Common Stock
Dec 05 2023	BUY Grant, award, or other acquisition	-	41,000 Added 40.42%	60,429 Common Stock
Oct 12 2023	BUY Open market or private purchase	$41,849 $8.37 p/Share	5,000 Added 20.47%	19,429 Common Stock
Dec 27 2021	SELL Open market or private sale	$232,250 $46.45 p/Share	5,000 Reduced 25.73%	14,429 Common Stock
Oct 11 2021	BUY Exercise of conversion of derivative security	$88,883 $6.16 p/Share	14,429 Added 42.62%	19,429 Common Stock
Jun 16 2021	BUY Open market or private purchase	$130,450 $26.09 p/Share	5,000 Added 50.0%	5,000 Common Stock

Matthew Gall

Chief Financial Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITOS shares.

Notify only if

Value

Insider Trading

Get notified when an I Teos Therapeutics, Inc. insider buys or sells ITOS shares.

Notify only if

Operation

Value

Type

News

Receive news related to iTeos Therapeutics, Inc.

Track Activities on ITOS

Account